Peloruside A enhances apoptosis in H-ras-transformed cells and is cytotoxic to proliferating T cells

Apoptosis

Volumn 9, Issue 6, 2004, Pages 785-796

  Miller, J H ^a   Rouwe B ^a,c   Gaitanos, T N ^a   Hood, K A ^a,d   Crume, K P ^a   Backstrom B T ^b   La Flamme, A C ^a   Berridge, M V ^b   Northcote, P T ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^c Ruakura Research Centre ^*  (Netherlands)

^d RUAKURA RESEARCH CENTRE   (New Zealand)

Author keywords

Caspase; Immunosuppression; Mycalamide; Pateamine; Peloruside; Ras

Indexed keywords

CASPASE 8; GAMMA INTERFERON; INTERLEUKIN 2; LIPOCORTIN 5; MARINE TOXIN; PELORUSIDE; PROPIDIUM IODIDE; TETRAZOLIUM; TRYPAN BLUE; UNCLASSIFIED DRUG; CD3 ANTIGEN; CROSS LINKING REAGENT; FUSED HETEROCYCLIC RINGS; LACTONE; PELORUSIDE A;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ASSAY; CELL CYCLE G2 PHASE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CROSS LINKING; CYTOKINE PRODUCTION; ENZYME ACTIVATION; GROWTH INHIBITION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; CELL LINE; CELL STRAIN HL 60; CELL TRANSFORMATION; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; METABOLISM; MIXED LYMPHOCYTE CULTURE; ONCOGENE RAS; TIME;

MYCALE HENTSCHELI;

ANIMALS; ANNEXIN A5; ANTIGENS, CD3; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL DEATH; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CROSS-LINKING REAGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENES, RAS; HL-60 CELLS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; LACTONES; LYMPHOCYTE CULTURE TEST, MIXED; MICE; T-LYMPHOCYTES; TIME FACTORS;

EID: 17444382251     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:APPT.0000045789.54694.cf     Document Type: Article

References (40)

1. West LM, Northcote PT, Battershill CH. Peloruside A: A potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem 2000; 65: 445-449.
2. Hood KA, Bäckström BT, West LM, Northcote PT, Berridge MV, Miller JH. The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C. Anti-Cancer Drug Design 2001; 16: 155-166.
3. Hood KA, West LM, Rouwé B, et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Canc Res 2002; 62: 3356-3360.
4. Perry NB, Blunt JW, Munro MH. Mycalamide A, an antiviral compound from a New Zealand sponge of the genus Mycale. J Am Chem Soc 1988; 110: 4850-4851.
5. Northcote P, Blunt J, Munro M. Pateamine: A potent cytotoxin from the New Zealand marine sponge, Mycale sp. Tetrahedron Lett 1991; 32: 6411-6414.
6. West LM, Northcote PT, Hood KA, Miller JH, Page MJ. Mycalamide D, a new cytotoxic amide from the New Zealand marine sponge Mycale species. J Nat Prod 2000; 63: 707-709.
7. Burres NS, Clement JJ. Antitumor activity and mechanism of action of the novel marine natural products Mycalamide-A and -B and Onnamide. Canc Res 1989; 49: 2935-2940.
8. Hood KA, West LM, Northcote PT, Berridge MV, Miller JH. Induction of apoptosis by the marine sponge (Mycale) metabolites, mycalamide A and pateamine. Apoptosis 2001; 6: 207-219.
9. Ogawara H, Higashi K, Uchino K, Perry NB. Change of ras-transformed NRK-cells back to normal morphology by mycalamides A and B, anti-tumor agents from a marine sponge. Chem Pharmacol Bull 1991; 39: 2152-2154.
10. Galvin F, Freeman GJ, Razi-Wolf, Benacerraf B, Nadler L, Reiser H. Effects of cyclosporin A, FK506, and mycalamide A on the activation of murine CD4+ T Cells by the murine B7 antigen. Eur J Immunol 1993; 23: 283-286.
11. Romo D, Rzasa RM, Shea HA, et al. Total synthesis and immunosuppressive activity of (-)-pateamine A and related compounds: Implementation of a β-lactam-based macrocyclization. J Am Chem Soc 1998; 120: 12237-12254.
12. Strasser A, O'Conner L, Dixit VM. Apoptosis signalling. Ann Rev Biochem 2000; 69: 217-245.
13. Buolamwini JK. Novel anticancer drug discovery. Curr Opin Chem Biol 1999; 3: 500-509.
14. Workman P, Kaye SB. Translating basic cancer research into new cancer therapeutics. Trends Molec Med 2002; 8 (No. 4 Suppl): S1-S9.
15. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'It ain't over 'til it's over'. Cell Biol 2000; 10: 147-154.
16. Malumbres M, Pellicer A. Ras pathways to cell cycle control and cell transformation. Frontiers Biosci 1998; 3: 887-912.
17. Ahmed N, Anderson SM, Berridge MV. IL-3 induces apoptosis in a ras-transformed myeloid cell line. Apoptosis 1999; 4: 1-10.
18. Bradford, MM. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analy Biochem 1976; 72: 248-254.
19. Kruisbeek AM, Shevach EM. Proliferative assays for T cell function. In: Coligan J, Kruisbeek AM, Margulies D, Shevach EM, Strober W, eds. Current Protocols in Immunology. New York: John Wiley and Sons, 1991: 3.12.1-3.12.14.
20. Yang X, Hayglass KT. A simple, sensitive, dual mAb based ELISA for murine gamma interferon determination: Comparison with two common bioassays. J Immunoassay 1993; 14: 129-148.
21. Berridge MV, Tan AS, McCoy KD, Wang R. The biochemical and cellular basis of cell proliferation assays that use tetrazolium salts. Biochemica 1996; 4: 14-19.
22. Seddon B, Kelland LR, Workman P. Bioreductive prodrugs for cancer therapy. Methods Mol Med 2004; 90: 515-542.
23. Berridge MV, Tan AS. High-capacity redox control at the plasma membrane of mammalian cells: Trans-membrane, cell surface, and serum NADH-oxidases. Antioxid Redox Signal 2000; 2: 231-242.
24. Irani K, Xia Y, Zweier JL, et al. Mitogenic signalling mediated by oxidants in ras-transformed fibroblasts. Science 1997; 275: 1649-1652.
25. Davis W Jr, Ronai Z, Tew KD. Cellular thiols and reactive oxygen species in drug-induced apoptosis. Persp Pharmacol 2001; 296: 1-6.
26. Liou JS, Chen C-Y, Chen JS, Faller DV. Oncogenic Ras mediates apoptosis in response to protein kinase C inhibition through the generation of reactive oxygen species. J Biol Chem 2000; 275: 39001-39011.
27. Scaffidi C, Fulda S, Srinvivasan A, et al. Two CD95 (apo-1/fas) signalling pathways. EMBO 1998; 17: 1675-1687.
28. Zhuang S, Simon G. Peroxynitrite-induced apoptosis involves activation of multiple caspases in HL-60 cells. Am J Physiol 2000; 279: C341-C351.
29. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2: 72-79.
30. Wang T-H, Wang H-S, Ichijo H, et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998; 273: 4928-4936.
31. Rakovitch E, Mellado W, Hall EJ, Pandita TK, Sawant S, Geard CR. Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation. Int J Rad Oncol Biol Phys 1999; 44: 1119-1124.
32. Reuter CWM, Morgan MA, Bergmann L. Targetting the Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies? Blood 1996: 96: 1655-1669.
33. Gallangher AP, Burnett AK, Bowen DT, Darley RL. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process. Canc Res 1998; 58: 2029-2035.
34. Ewen ME. Relationship between Ras pathways and cell cycle control. Prog Cell Cycle Res 2000; 4: 1-17.
35. Bergamaschi D, Ronzoni S, Taverna S, et al. Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound. Br J Cancer 1999; 79: 267-277.
36. Zhang X, Minale L, Zampella A, Smith CD. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides. Cancer Res 1997; 57: 3751-3758.
37. Shapiro GI, Harper JW. Anticancer drug targets: Cell cycle and checkpoint control. J Clin Invest 1999; 104: 1645-1653.
38. Sharma VK, Li B, Khanna A, Sehajpal PK, Suthanthiran M. Which way for drug-mediated immunosuppression? Curr Opin Immunol 1994; 6: 784-790.
39. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc Natl Acad Sci USA 1992; 89: 3686-3690.
40. Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989; 246: 1617-1620.